Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment.

Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT.

ACS Nano. 2013 Nov 26;7(11):9571-84. doi: 10.1021/nn4047925. Epub 2013 Oct 21.

2.

"Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.

Su S, Tian Y, Li Y, Ding Y, Ji T, Wu M, Wu Y, Nie G.

ACS Nano. 2015 Feb 24;9(2):1367-78. doi: 10.1021/nn505729m. Epub 2015 Jan 26.

PMID:
25611071
3.

Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.

Andey T, Sudhakar G, Marepally S, Patel A, Banerjee R, Singh M.

Mol Pharm. 2015 Apr 6;12(4):1105-20. doi: 10.1021/mp5008629. Epub 2015 Mar 2.

PMID:
25661724
4.

Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S, Wang X, Zhao Y, Ji Z, Zink JI, Nel AE.

ACS Nano. 2013 Feb 26;7(2):994-1005. doi: 10.1021/nn3044066. Epub 2013 Jan 4.

5.

Role of integrated cancer nanomedicine in overcoming drug resistance.

Iyer AK, Singh A, Ganta S, Amiji MM.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802. doi: 10.1016/j.addr.2013.07.012. Epub 2013 Jul 21. Review.

PMID:
23880506
6.

Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs.

Ramasamy T, Haidar ZS, Tran TH, Choi JY, Jeong JH, Shin BS, Choi HG, Yong CS, Kim JO.

Acta Biomater. 2014 Dec;10(12):5116-27. doi: 10.1016/j.actbio.2014.08.021. Epub 2014 Aug 25.

PMID:
25169256
7.

Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.

Wang H, Zhao Y, Wang H, Gong J, He H, Shin MC, Yang VC, Huang Y.

J Control Release. 2014 Oct 28;192:47-56. doi: 10.1016/j.jconrel.2014.06.051. Epub 2014 Jul 6.

PMID:
25003794
8.

Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.

Wang H, Li F, Du C, Wang H, Mahato RI, Huang Y.

Mol Pharm. 2014 Aug 4;11(8):2600-11. doi: 10.1021/mp400687w. Epub 2014 Jan 17.

PMID:
24405470
9.

Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.

Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, Nel AE.

ACS Nano. 2010 Aug 24;4(8):4539-50. doi: 10.1021/nn100690m.

10.

Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.

Jiang J, Yang SJ, Wang JC, Yang LJ, Xu ZZ, Yang T, Liu XY, Zhang Q.

Eur J Pharm Biopharm. 2010 Oct;76(2):170-8. doi: 10.1016/j.ejpb.2010.06.011. Epub 2010 Jun 25.

PMID:
20600887
11.

Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound.

Bai M, Shen M, Teng Y, Sun Y, Li F, Zhang X, Xu Y, Duan Y, Du L.

Oncotarget. 2015 Dec 22;6(41):43779-90. doi: 10.18632/oncotarget.6085.

12.

Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.

Ma X, Teh C, Zhang Q, Borah P, Choong C, Korzh V, Zhao Y.

Antioxid Redox Signal. 2014 Aug 10;21(5):707-22. doi: 10.1089/ars.2012.5076. Epub 2013 Sep 28.

PMID:
23931896
13.

Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.

Li YT, Chua MJ, Kunnath AP, Chowdhury EH.

Int J Nanomedicine. 2012;7:2473-81. doi: 10.2147/IJN.S30500. Epub 2012 Jun 5.

14.

Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.

Babu A, Wang Q, Muralidharan R, Shanker M, Munshi A, Ramesh R.

Mol Pharm. 2014 Aug 4;11(8):2720-33. doi: 10.1021/mp500259e. Epub 2014 Jun 20.

PMID:
24922589
15.

Osteotropic therapy via targeted layer-by-layer nanoparticles.

Morton SW, Shah NJ, Quadir MA, Deng ZJ, Poon Z, Hammond PT.

Adv Healthc Mater. 2014 Jun;3(6):867-75. doi: 10.1002/adhm.201300465. Epub 2013 Oct 9.

16.

Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.

Wu Y, Zhang Y, Zhang W, Sun C, Wu J, Tang J.

Colloids Surf B Biointerfaces. 2016 Feb 1;138:60-9. doi: 10.1016/j.colsurfb.2015.11.041. Epub 2015 Nov 25.

PMID:
26655793
17.

Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.

Li JM, Zhang W, Su H, Wang YY, Tan CP, Ji LN, Mao ZW.

Int J Nanomedicine. 2015 Apr 23;10:3147-62. doi: 10.2147/IJN.S67146. eCollection 2015.

18.

Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.

Alinejad V, Hossein Somi M, Baradaran B, Akbarzadeh P, Atyabi F, Kazerooni H, Samadi Kafil H, Aghebati Maleki L, Siah Mansouri H, Yousefi M.

Biomed Pharmacother. 2016 Oct;83:229-240. doi: 10.1016/j.biopha.2016.06.037. Epub 2016 Jun 30.

PMID:
27372407
19.

siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells.

Dong X, Liu A, Zer C, Feng J, Zhen Z, Yang M, Zhong L.

BMC Cancer. 2009 May 5;9:133. doi: 10.1186/1471-2407-9-133.

20.

Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

Saad M, Garbuzenko OB, Minko T.

Nanomedicine (Lond). 2008 Dec;3(6):761-76. doi: 10.2217/17435889.3.6.761.

Supplemental Content

Support Center